Exposure to attention deficit hyperactivity disorder medications during pregnancy

Caitlin Humphreys, Facundo Garcia-Bournissen, Shinya Ito, Gideon Koren

Research output: Contribution to journalShort surveypeer-review

26 Scopus citations


QUESTION: An 18-year-old patient of mine, currently under treatment for attention deficit hyperactivity disorder (ADHD) with methylphenidate, just found out that she is pregnant. What are the risks for the baby when the mother uses ADHD medications during pregnancy? ANSWER: Available evidence for amphetamines suggests no increased risk of malformations with use of therapeutic doses, and inadvertent exposure during pregnancy is unlikely to be harmful. Human data for methylphenidate and atomoxetine treatment in pregnancy are very limited. Documented cases do not suggest teratogenicity, but we cannot rule out this risk with the information available.

Original languageEnglish
Pages (from-to)1153-1155
Number of pages3
JournalCanadian Family Physician
Issue number7
StatePublished - Jul 2007


Dive into the research topics of 'Exposure to attention deficit hyperactivity disorder medications during pregnancy'. Together they form a unique fingerprint.

Cite this